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Introduction
Autologous platelet rich plasma (PRP) is a biologic
utilized to stimulate the healing of damaged tissues. It is
composed of various lipids. One active component to PRP’s
lipid fraction are eicosanoids, bioactive signaling lipids
derived from ω-3 and ω-6 polyunsaturated fatty acids
(PUFAs)1. Current dogma suggests that ω-3 PUFAs (eg a
high ω-3:ω-6 ratio) and its eicosanoids can promote health
in humans. This is achieved classically by these eicosanoids
acting in autocrine and paracrine circuits3, prompting lower
systemic inflammation by modulation of lymphocyte
proliferation and cytokine production2,3. These eicosanoids
are time sensitive mediators of inflammation synthesized at
sites of tissue damage whose dysregulation are associated
with pathological tissue repair1. While diverse in structure
and function, ω-3 and ω-6 derived eicosanoids share
common enzymatic pathways like the cyclooxygenase
(COX) pathway and therefore compete.
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as
aspirin modulate eicosanoids by inhibiting their
aforementioned proinflammatory COX pathway, triggering
aspirin-specialized proresolving lipid mediator production
pathways3. The ratio or “balance” of proinflammatory and
proresolving lipids are dependent in part on the availability
of their precursor lipids1. These lipids’ bioavailability in the
blood and their efficacy for clinical use are current, ongoing
areas of research1,3. We investigated whether the short-term
alteration of the ω-3/ω-6 ratio led to the production of PRP
with a more proresolving lipid profile. Granted the diversity
of these lipid species, the relative abundance of eicosanoids
and their precursors must be measured when assessing






This prospective study demonstrates that short-term or acute
administration of PUFAs can yield exogenous, modulatory effects
on PRP’s lipid fraction. A pronounced fluctuation in circulatory ω-6
PUFAs and their derivatives, such as those within the oxylipin
profile (eg 12,13 diHOME and 11,12 EET), occurred in the fish oil
treatment group with some similarities observed in the aspirin and
combinational therapy groups. When compared to the control’s
correlations, inverse correlations were observed in the fish oil
treatment group between ω-6 PUFA arachidonic acid (FFA 20:4)
and prostaglandins, resolvins, and thromboxanes. Quantification of
ω-3, ω-6 PUFAs, and their metabolites offers an insightful snapshot
of the biologically available lipids following supplementation. Larger
future studies that leverage varying doses of fish oil, and further
explores these underlying mechanistic pathways, could evaluate the
efficacy of PRP therapy. These studies would support a
comprehensive framework to further optimize PRP for treatment of
inflammatory diseases.
Platelet rich plasma (PRP) at baseline and 6-hours was
collected from 47 patients randomly assigned to either placebo,
one soft-gel Fish oil tablet (1400 mg, Sundown Naturals, NY),
Bayer low-dose aspirin (81mg), or combinational therapy.
Targeted analysis of eicosanoids and select PUFAs was
conducted by liquid chromatography tandem mass spectrometry
via a TripleTOF 6600 mass spectrometry paired to an Agilent
1290 liquid chromatograph (LC). Remaining lipids were acquired
by direct infusion via a 5600+ TripleTOF mass spectrometry
(ScieX). Eicosanoids were normalized as a ratio of area to their
internal standard; all lipids other than eicosanoids were
expressed as mol%. Data were log transformed and Pareto
scaled to correct for variances in lipid class abundance. Outliers
were detected by the 1.5 x the interquartile range (IQR) and
winsorized within treatment groups by 25th and 75th percentiles.
One-way analysis of variance (ANOVA) with Tukey’s honestly
significant difference (Tukey HSD) post-hoc test was performed
to determine the interaction of group and time on lipid
modulation. FDR-adjustment was performed to correct for
multiple testing. Spearman’s correlation analysis presented any
correlations between PUFAs and major lipid classes against
eicosanoids. All analyses were conducted in MetaboAnalyst 5.0,
JMP Pro 15.1.0, and in-house R scripts (version 4.0.3).
Figure 1: Comparisons of PRP PUFAs demonstrate
modulation after 6 hours of fish oil treatment and aspirin.
Precursor ω-6 linoleic acid (FFA 18:2) and derivative arachidonic
acid (FFA 20:4) were reduced in fish oil. With fish oil
supplementation, the ω-6 PUFAs docosahexaenoic acid (FFA
22:6) and docosapentaenoic acid (FFA 22:5) were also reduced.
Brackets represent Tukey HSD adjusted p-values.
Figure 2: Comparisons of PRP eicosanoids demonstrates
modulation after 6 hours of fish oil treatment and aspirin.
These oxylipins and other and other ω-6 derivatives were
differentially modulated by supplementation of fish oil. To
note, some lipids were similarly affected in fish oil in aspirin or
combinational therapy. Brackets represent Tukey HSD
adjusted p-values.
Figure 3: Comparisons of glycerolipid species
demonstrates peripheral lipids influenced by Fish Oil
treatment. Tri/diacylglycerols involved in ω-3 and ω-6
metabolism offers insight into the flux of bioactive lipids in
PRP. Brackets represent Tukey HSD adjusted p-values.
Figure 3: Spearman rank correlation for PUFA into
eicosanoids. Correlations reported for fish oil group, cross
referenced against control. Correlated PUFAs include ω-6
Arachidonic acid (FFA 20:4), and ω-3 Eicosapentaenoic acid
(FFA 20:5) and Docosahexaenoic acid (FFA 22:6).
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⬤ Baseline ⬤ Placebo  ⬤ FIsh Oil  ⬤ Aspirin ⬤ Both Treatments
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DAG 40:8 (FFA 22:6)
ANOVA FDR-adjusted, p =  0.00196
TAG 57:9 (FFA 22:5)
ANOVA FDR-adjusted, p =  0.0229
TAG 57:4 (FFA 18:2)
ANOVA FDR-adjusted, p =  0.000735
ANOVA FDR-adjusted, p =  0.000173
12,13 diHOME
ANOVA FDR-adjusted, p =  0.000277
11,12 EET
ANOVA FDR-adjusted, p =  0.00779
11 HEPE
ANOVA FDR-adjusted, p =  0.0127
8 HETE
ANOVA FDR-adjusted, p =  0.0158
9 HETE
ANOVA FDR-adjusted, p =  0.000264
18 HETE
ANOVA FDR-adjusted, p =  4.52e-06
Arachidonic Acid (FFA 20:4)
ANOVA FDR-adjusted, p =  0.000277
Linoleic Acid (FFA 18:2)
ANOVA FDR-adjusted, p =  0.00823
Docosahexaenoic Acid (FFA 22:6)
ANOVA FDR-adjusted, p =  0.005575
Docosapentaenoic Acid (FFA 22:5)
